Patents by Inventor Cleva Villanueva

Cleva Villanueva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11439606
    Abstract: A treatment for a hyperglycemic condition, including diabetes mellitus, includes the step of administering to a human being dimethylformamide (“DMF”), which has the chemical structural formula: DMF can be administered to the human patient in a wide variety of ways, however it is preferable that the administration of DMF be performed orally and the dose of DMF could be combined with numerous inert substances known to the prior art, such as a sugarless fruit juice concentrate. The preferred daily dosage of DMF administered to a person would be about 0.041 mg/kg body weight to about 1.23 mg/kg of body weight of the person.
    Type: Grant
    Filed: December 1, 2019
    Date of Patent: September 13, 2022
    Inventors: Robert D. Kross, Guadalupe Cleva Villanueva Lopez
  • Publication number: 20200170969
    Abstract: A treatment for a hyperglycemic condition, including diabetes mellitus, includes the step of administering to a human being dimethylformamide (“DMF”), which has the chemical structural formula: DMF can be administered to the human patient in a wide variety of ways, however it is preferable that the administration of DMF be performed orally and the dose of DMF could be combined with numerous inert substances known to the prior art, such as a sugarless fruit juice concentrate. The preferred daily dosage of DMF administered to a person would be about 0.041 mg/kg body weight to about 1.23 mg/kg of body weight of the person.
    Type: Application
    Filed: December 1, 2019
    Publication date: June 4, 2020
    Inventors: Robert D. Kross, Guadalupe Cleva Villanueva Lopez
  • Publication number: 20130323326
    Abstract: A composition and method are described for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition. Fibrous adhesions typically form during healing of tissue, for example following a surgical procedure. A multicomponent oxychlorine composition is provided for irrigating the tissue which minimizes post-surgical adhesion formation, the composition containing both chlorine dioxide and chlorite ion, and a complex ion thereof. The chlorine dioxide level generally is in an effective range of ClO2 concentration from about 10 ppm to a maximum of about 110 ppm. In a preferred embodiment, a physiological composition is provided in a thickened form to increase retention in the area being treated.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 5, 2013
    Inventors: Robert D. Kross, Cleva Villanueva
  • Patent number: 8507011
    Abstract: A composition and method are described for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition. Fibrous adhesions typically form during healing of tissue, for example following a surgical procedure. A multicomponent oxychlorine composition is provided for irrigating the tissue which minimizes post-surgical adhesion formation, the composition containing both chlorine dioxide and chlorite ion, and a complexion thereof. The chlorine dioxide level generally is in an effective range of ClO2 concentration from about 10 ppm to a maximum of about 110 ppm. In a preferred embodiment, a physiological composition is provided in a thickened form to increase retention in the area being treated.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: August 13, 2013
    Inventors: Robert D. Kross, Cleva Villanueva
  • Publication number: 20100330203
    Abstract: A composition and method are described for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition. Fibrous adhesions typically form during healing of tissue, for example following a surgical procedure. A multicomponent oxychlorine composition is provided for irrigating the tissue which minimizes post-surgical adhesion formation, the composition containing both chlorine dioxide and chlorite ion, and a complex ion thereof. The chlorine dioxide level generally is in an effective range of ClO2 concentration from about 10 ppm to a maximum of about 110 ppm. In a preferred embodiment, a physiological composition is provided in a thickened form to increase retention in the area being treated.
    Type: Application
    Filed: March 19, 2010
    Publication date: December 30, 2010
    Inventors: Robert D. Kross, Cleva Villanueva